Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Resource: A compendium of HLA types and expression in pediatric cancer models.
Guan Y et al.
Iscience, 2025
ClinVar: updates to support classifications of both germline and somatic variants.
Landrum MJ et al.
Nucleic Acids Research, 2025
Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology.
Jimmidi R et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
H3K27M mutant glioma: Disease definition and biological underpinnings.
Saratsis AM et al.
Neuro-oncology, 2024
Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts.
Reissig TM et al.
Molecular Oncology, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Mutational landscape of cancer-driver genes across human cancers.
Sinkala M
Scientific Reports, 2023
A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.
McNicholas M et al.
Cancer Discovery, 2023
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
Ocasio JK et al.
Cancer Metastasis Reviews, 2023
A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders.
Katagiri T et al.
Nature Communications, 2023
Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting.
Nagar G et al.
Briefings in Functional Genomics, 2023
Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
Ajuyah P et al.
Scientific Reports, 2023
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML et al.
Neuro-oncology, 2022
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5.
Sun Y et al.
Nature Cancer, 2022
Recurrent ACVR1 mutations in posterior fossa ependymoma.
Pratt D et al.
Acta Neuropathologica, 2022
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.
Carvalho DM et al.
Cancer Discovery, 2022
Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.
Katagiri T et al.
Biomedicines, 2021
Symmetrical glial hyperplasia in the brainstem of fibrodysplasia ossificans progressiva.
Mori S et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2021
Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.
Khan F et al.
Biomedicines, 2021
Brain stem gliomas and current landscape.
Wummer B et al.
Journal of Neuro-oncology, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
The mechanistic GEMMs of oncogenic histones.
Lindroth AM et al.
Human Molecular Genetics, 2020
Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
Graham MS et al.
International Journal of Molecular Sciences, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
Sarthy JF et al.
Elife, 2020
Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene.
Matsuoka M et al.
Bone, 2020
Clinical, radiological and molecular characterization of intramedullary astrocytomas.
Lebrun L et al.
Acta Neuropathologica Communications, 2020
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H et al.
Scientific Reports, 2020
Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Fortin J et al.
Cancer Cell, 2020
ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
Sekimata K et al.
Chemical & Pharmaceutical Bulletin, 2020
Signal Transduction in Diffuse Intrinsic Pontine Glioma.
Duchatel RJ et al.
Proteomics, 2019
Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
Qi J et al.
Acta Neuropathologica Communications, 2019
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
Hoeman CM et al.
Nature Communications, 2019
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma.
Carvalho D et al.
Communications Biology, 2019
Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities.
Gojo J et al.
Frontiers in Oncology, 2019
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
Panditharatna E et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Machiya A et al.
Bone, 2018